Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?

Despite several clinical trials have assessed different agents in the adjuvant setting, renal cell carcinoma (RCC) still remains a disease orphan of an effective adjuvant treatment. In fact, systemic therapies targeting angiogenesis that have been observed to be effective in metastatic setting faile...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transl Androl Urol
Prif Awduron: Mollica, Veronica, Rizzo, Alessandro, Di Nunno, Vincenzo, Santoni, Matteo, Cheng, Liang, Lopez-Beltran, Antonio, Scarpelli, Marina, Cimadamore, Alessia, Montironi, Rodolfo, Massari, Francesco
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AME Publishing Company 2021
Pynciau:
Review Article on Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039625/
https://ncbi.nlm.nih.gov/pubmed/33850792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tau-20-1125
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg